相关实验视频

Updated: Jul 14, 2026

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

在小鼠模型中,cysteinyl leukotriene受体-1作为宿主导疗法的潜在标,用于慢性杆菌病期间的宿主导疗法

Paballo Mosala^1,2, Thabo Mpotje^1,2, Nada Abdel Aziz^1,2,3

¹Institute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology and South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Frontiers in immunology

|June 6, 2024

概括

抑制cysteinyl leukotriene受体1 (cysLTR1) 降低了杆菌病的炎症和纤维化. 将蒙特卢卡斯特与普拉齐昆结合,为这种被忽视的热带疾病提供了潜在的新治疗策略.

科学领域:

免疫学免疫学免疫学
热带医学热带医学
药物发现药物发现药物发现

背景情况:

湿病是一种主要的被忽视的热带疾病,影响全球数百万人,其特点是慢性炎症和纤维化.
普拉西昆特 (PZQ) 是主要的治疗方法,但再次感染需要新的治疗策略.
乙氨基白血 (cysLTs) 涉及炎症性疾病,可能在杆菌病理学中发挥作用.

研究的目的:

为了研究cysteinyl leukotriene受体1 (cysLTR1) 在实验性杆菌病中的作用.
评估单独或与PZQ结合阻断cysLTR1的治疗潜力,用于治疗杆菌病.

主要方法:

使用了cysLTR1-缺乏 (cysLTR1-/-) 的小鼠和被感染*Schistosoma mansoni*的野生类型幼对照.
单独或与PZQ结合,给慢性感染的小鼠服用一种cysLTR1抑制剂蒙特卢卡斯特.
评估了肝脏颗粒状炎症,纤维化,IL-4产生,寄生虫卵负担和调节性T细胞 (Treg) 扩张.

主要成果:

缺乏cysLTR1的小鼠在慢性杆菌病中显著减少肝炎,纤维化和IL-4的产生.
蒙特卢卡斯特与PZQ结合使用,降低了慢性感染小鼠的肝炎和卵子负担.
组合疗法促进了Treg扩张,并通过减少纤维细胞瘤病理来显示预防性治疗的潜力.

结论:

cysLTR1在缓解杆菌体病变期间的纤维细胞瘤病理中发挥着重要作用.
干扰cysLTR1对宿主生存并不重要,这表明它在调节免疫反应中的作用.
蒙特卢卡斯特和PZQ的组合代表了一种有前途的宿主导治疗方法来治疗杆菌病.

关键词:

Th2 免疫反应的免疫反应半乙基白血1 (CYSLTR1) 是一种主体导向疗法主体导向疗法蒙特鲁卡斯塔尔是世界上最古老的实际上,这是一个很好的方法.这种疾病叫做schistosomiasis.

更多相关视频

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Experimental Infection of Mice with the Parasitic Nematode Strongyloides ratti ratti Infection

Experimental Infection of Mice with the Parasitic Nematode Strongyloides ratti ratti Infection

Published on: January 17, 2025

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...